EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD

EyePoint, Inc.

2025-Q2 EPS reported -$1.50 vs consensus -$0.81 ▼ miss (-84.5%)

Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.
Total operating expenses $67.6M, up from $44.0M, driven by DURAVYU Phase 3 trial costs.
Cash, equivalents and marketable securities $256M as of June 30, 2025; cash runway into 2027.
Completed enrollment in both Phase 3 wet AMD trials (LUGANO and LUCIA) with over 800 patients; topline LUGANO data mid-2026.
Initiated DURAVYU registration batches at Northbridge, MA commercial manufacturing facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.